Clinical Trial: Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients

U.S., July 22 -- ClinicalTrials.gov registry received information related to the study (NCT07715929) titled 'Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients' on July 15.

Brief Summary: Obese patients with atrial fibrillation (AF) have a high recurrence rate after catheter ablation, even at experienced centers. Weight reduction improves post-ablation outcomes, but lifestyle measures alone are difficult to sustain. Tirzepatide, a once-weekly GIP/GLP-1 dual receptor agonist, produces greater weight loss than GLP-1 monotherapy and may confer additional cardiometabolic benefits. This multicenter, randomized, open-label, parallel-group, superiority trial evaluates whether adding standardized t...